Literature DB >> 6100426

Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection.

P A Anton, J A Kemp, T Butler, M R Jacobs.   

Abstract

The activities of ceftriaxone, moxalactam, and ampicillin against Salmonella typhimurium LT-2 were compared in culture media at pH 5, 6, 7 and 8 and in mice inoculated intraperitoneally. The minimal inhibitory concentrations for strain LT-2 in Mueller-Hinton broth were 0.03 microgram of ceftriaxone per ml, 0.08 microgram of moxalactam per ml, and 0.4 microgram of ampicillin per ml. A comparison of minimal inhibitory concentrations in buffered broth at pH 5 with those in media at higher pH values showed that ceftriaxone was more acid stable than the other antibiotics. Groups of CF-1 female mice inoculated intraperitoneally with 3 X 10(4) colony-forming units received saline or each drug in fourfold decremental doses by the subcutaneous route every 8 h for 3 days, beginning at 24 h after challenge. The mean log 10 colony-forming units of S. typhimurium per spleen at the end of treatment and the mortality rates at 21 days after inoculation were measured for each treatment group. The mean log 10 colony-forming units per spleen was significantly reduced from that of the saline control by dosages of greater than or equal to 0.06 mg of ceftriaxone per kg, 64 mg of moxalactam per kg, or greater than or equal to 16 mg of ampicillin per kg (P less than 0.05). Mortality rates of infected mice were significantly reduced by dosages of greater than or equal to 1 mg of ceftriaxone per kg or greater than or equal to 64 mg of ampicillin per kg (P less than 0.05), whereas moxalactam in dosages as high as 16 mg/kg did not significantly reduce mortality rate. These results demonstrate the superiority of ceftriaxone to the other tested antibiotics on a weight basis in this model of experimental Salmonella infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6100426      PMCID: PMC183731          DOI: 10.1128/AAC.22.2.312

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Authors:  R Reiner; U Weiss; U Brombacher; P Lanz; M Montavon; A Furlenmeier; P Angehrn; P J Probst
Journal:  J Antibiot (Tokyo)       Date:  1980-07       Impact factor: 2.649

2.  Ro 13-9904 and GR 20263, two new cephalosporins with broad-spectrum activity: an in vitro comparison with other beta-lactam antibiotics.

Authors:  A M Clarke; S J Zemcov
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

3.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

4.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin.

Authors:  M Seddon; R Wise; A P Gillett; R Livingston
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

6.  In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins.

Authors:  S Shelton; J D Nelson; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

7.  Treatment of experimental Salmonella typhimurium infection with mecillinam and ampicillin.

Authors:  T Butler; C W Shuster; P Dixon
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

8.  Effect of a Salmonella group H1 R factor on virulence and response of infections to antimicrobial therapy.

Authors:  T Butler; C W Shuster; A Franco
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

9.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.

Authors:  W M Scheld; D A Spyker; G R Donowitz; W K Bolton; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

View more
  11 in total

1.  Oral ciprofloxacin treatment for Salmonella typhimurium infection of normal and immunocompromised mice.

Authors:  H Brunner; H J Zeiler
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 2.  Therapy of patients with resistant bacterial infections.

Authors:  J J Rahal
Journal:  Bull N Y Acad Med       Date:  1987-04

3.  Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis.

Authors:  M L Fernández Guerrero; R Torres Perea; C Verdejo Morcillo; R Fernández Roblas; M de Górgolas
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

4.  Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp.

Authors:  S R Preblud; C J Gill; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial.

Authors:  I Kabir; T Butler; A Khanam
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

7.  Pharmacokinetics of ceftriaxone in patients with typhoid fever.

Authors:  G Acharya; C Crevoisier; T Butler; M Ho; M Tiwari; K Stoeckel; C A Bradley
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy.

Authors:  T Butler; M Ho; G Acharya; M Tiwari; H Gallati
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

9.  Therapy of experimental meningitis due to Salmonella enteritidis.

Authors:  J P Bryan; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles.

Authors:  E Fattal; M Youssef; P Couvreur; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.